anti-PAD2/anti-PAD4 bispecific humanized mAb (Shanghai Qilu Pharmaceutical)

N/A

Report date: 2025/03/14 16:22:38

Base Information

Drug Nameanti-PAD2/anti-PAD4 bispecific humanized mAb (Shanghai Qilu Pharmaceutical)
Drug Alias Namepeptidyl arginine deaminase 2/4 bispecific humanized mAb (Shanghai Qilu Pharmaceutical)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProtein-arginine deiminase type-2 inhibitorsProtein-arginine deiminase type-4 inhibitors
TargetsProtein-arginine deiminase type-4Protein-arginine deiminase type-2
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesQilu Pharma Spain Sa
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharma Spain Sa
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A